Picture loading failed.

Anti-CD40 therapeutic antibody (Pre-made Selicrelumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Selicrelumab (also known as RO 7009789, RG 7876) is a monoclonal antibody agonist of the cell surface receptor CD40, that is being developed by Roche for the treatment of solid tumours, B cell lymphomas and pancreatic cancer.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-511-1mg 1mg 3090
GMP-Bios-ab-511-10mg 10mg 21890
GMP-Bios-ab-511-100mg 100mg 148000
GMP-Bios-ab-511-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD40 therapeutic antibody (Pre-made Selicrelumab biosimilar,Whole mAb)
INN Name Selicrelumab
TargetCD40
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesAbramson Cancer Center of the University of Pennsylvania;Roche
Conditions Approvedna
Conditions ActivePancreatic cancer;Solid tumours
Conditions Discontinuedna
Development Techna